Matthew A. Lunning, DO, FACP

Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.

A deep dive into treatment sequencing strategies in R/R DLBCL, sharing insights from clinical data and recently approved novel therapies.

Expert shares clinical perspectives and treatment considerations regarding use of later lines of therapy for patients with R/R diffuse large B-cell lymphoma.

Matthew Lunning, DO, FACP, evaluates the clinical trial data from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on real-world outcomes.

Dr. Lunning, an expert in lymphoma, discusses the results and clinical significance of the LOTIS-2 trial, evaluating loncastuximab tesirine for patients with R/R DLBCL.

A comprehensive overview of third-line relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and bispecific antibodies.

Expert Matthew Lunning, DO, FACP, reviews the case of a 73-year-old woman with R/R DLBCL, considering current and emerging treatment strategies in this setting.

A glimpse into the ever-changing treatment landscape of DLBCL, exploring frontline therapy options and the potential for tailoring treatments based on novel agents and randomized trials.

Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.

A comprehensive exploration of CAR T-cell therapy and additional agents such as loncastuximab in relapsed/refractory DLBCL, emphasizing clinical findings and treatment considerations.

A deep dive into the use of Polatuzumab Vedotin in DLBCL treatment, including insights from clinical trials and innovative strategies.

Matthew Lunning, DO, FACP, further explores relapsed/refractory DLBCL treatment strategies and clinical trial findings from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on patient outcomes.

An in-depth examination of relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and tafasitamab, based on clinical trial data and patient eligibility.

Expert insights into a 67-year-old man's journey through relapsed/refractory diffuse large B-cell lymphoma, exploring diagnosis, treatment options, and outcomes.

Expert Matthew Lunning, DO, FACP, shares his excitement for an upcoming case-based peer perspectives program wherein he reviews the diagnosis and management of a patient with DLBCL, considering evolving treatment paradigms and updated clinical data.

Dr Matthew Lunning closes his discussion on DLBCL by highlighting unmet needs in the treatment landscape.

Matthew Lunning, DO, FACP, shares data from the RE-MIND2 trial and explains how it compares to the L-MIND trial.

A review of the methods and data from a clinical trial investigating a combination therapy for relapsed/refractory DLBCL.

Dr Matthew Lunning describes the available third- and subsequent-line treatments for patients with relapsed/refractory DLBCL (R/R DLBCL) who aren’t eligible for transplant.

An expert explains the options for patients with DLBCL who develop chemorefractory disease in second-line treatment.

Matthew Lunning, DO, FACP, presents the case of a 64-year-old man with diffuse large B-cell lymphoma (DLBCL) and shares his initial impressions.

Dr Lunning reviews potential options for later line therapy for patients with R/R DLBCL and shares his thought about future directions in the evolving treatment landscape.

Matthew Lunning, DO, presents the efficacy and safety findings of the L-MIND trial in relapsed/refractory diffuse large B-cell lymphoma and discusses the implications for clinical practice.

Dr Matthew Lunning reviews second-line treatment options for patients with R/R DLBCL and provides insight on individualizing therapy.

DLBCL expert Matthew Lunning, DO, describes risk assessment in patients with DLBCL and how it informs first-line treatment choice.

Matthew Lunning, DO, presents a case of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma and discusses considerations for therapy.

Matthew Lunning, DO, presents a case study of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma.